Taken together, these findings further validated the occurrence of glucose metabolic reprogramming in CCA and identified the presence of KRAS mutations as candidate drivers for the activation of the serine-glycine pathway in this type of tumour. The gene discussed is KRAS; the disease is cholangiocarcinoma.